期刊文献+

角膜穿孔伤对环丙沙星在兔眼内渗透性的影响

下载PDF
导出
摘要 目的研究角膜穿孔伤兔眼血-眼屏障的改变以及静脉注射环丙沙星后药物在眼内的渗透性。方法15兔各右眼为实验组,左眼为对照组。右眼行角膜穿孔伤后1h静脉注射环丙沙星,用药后0.5h,取房水及玻璃体,用反向高效液相色谱法测定环丙沙星浓度,用双缩脲法测定房水蛋白含量。结果实验组房水蛋白含量(12.641±6.786)g/L高于对照组的(2.739±1.111)g/L(P<0.01);实验组房水环丙沙星浓度(1.365±0.588)ng/ml高于对照组的(0.669±0.329)μg/ml(P<0.01);房水蛋白的含量与房水环丙沙星的浓度呈正相关,相关系数r=0.677(P<0.01)。实验组和对照组玻璃体中环丙沙星浓度均很低,两组之间的差异无显著性(P>0.05)。结论角膜穿孔伤可以影响血-房水屏障,使其通透性明显增加;房水中环丙沙星的水平也明显提高,其浓度显著高于大部分眼内致病菌90%菌株最小抑菌浓度(MIC90s),为环丙沙星作为角膜穿孔伤和白内障手术后性眼内炎静脉预防性用药提供实验依据。
出处 《广东医学》 CAS CSCD 北大核心 2008年第9期1461-1463,共3页 Guangdong Medical Journal
基金 广东省中医药管理局科研基金资助项目(编号:1050065)
  • 相关文献

参考文献10

  • 1ESSEX R W, YI Q, CHARLES P G, et al. Post -traumatic endophthalmitis[ J]. Ophthalmology, 2004, 111 ( 11 ) : 2 015 - 2 022.
  • 2BUZARD K, LIAPIS S. Prevention of endophthalmitis[ J]. Cataract Refract Surg, 2004, 30(9) : 1 953 -1 959.
  • 3王玲,孙悦,王美娟.血—房水屏障破坏与PcIOL前纤维蛋白膜形成的关系[J].上海交通大学学报(医学版),2001,25(6):523-526. 被引量:2
  • 4MONDINO B J, RAO H. Complement levels in nomal and in flamed aqueous humor[ J]. Invest Ophthalmov Vis Sci, 1993, 25 (1): 80.
  • 5SOULI M, KOPSINIS G, KAVOUKLIS E, et al. Vancomycin levels in human aqueous humour after intravenous and subconjunctival administration[ J]. Int J Antimicrob Agents, 2001, 18 (3) : 239 - 439.
  • 6朱曼,王睿.第四代氟喹诺酮类抗菌药——加替沙星[J].中国临床药理学与治疗学,2001,6(4):377-381. 被引量:71
  • 7ALFARO D V, HUDSON S J, RAFANAN M M, et al. The effect of trauma on the ocular penetration of intravenous ciprofloxacin [J]. Am J Ophthalmol, 1996, 122(5):679-683.
  • 8王伟,徐海峰,原公强,潘晓钢,董晓光.外伤性感染性眼内炎病因和致病菌临床分析[J].眼外伤职业眼病杂志,2002,24(5):490-492. 被引量:38
  • 9王伟,彭春霞,臧新杰,徐海峰.玻璃体腔注射乳酸环丙沙星对视网膜影响的研究[J].中华眼底病杂志,2005,21(3):180-182. 被引量:2
  • 10CEKIC O, BATMAN C, YASAR U, et al. Human aqueous and vitreous humour levels of ciprofloxacin following oral and topical administration[J]. Eye, 1999, 13(6) : 555 -558.

二级参考文献28

  • 1赵树清,王金生.新型氟喹诺酮抗菌剂——AM—1155[J].中国医药情报,1996,2(4):249-252. 被引量:4
  • 2Kowalski RP, Karenchak LM,Eller AW. The role of ciprofoxacin in endophthalmitis therapy. Am J Ophthalmol, 1993,116: 695-699.
  • 3樊德厚 王永利.中国药物大全(第2版)[M].北京:人民卫生出版社,2000.323-324.
  • 4Lesk MR,Ammann H, Marcil G, et al. The penetration of oral ciproflaxacin into the aqueous humor, vitreous,and subretinal fluid of humans. Am J Ophthalmol, 1993,115:623-628.
  • 5Marchese AL, Slana VS, Holmes EW, et al. Toxicity and pharmakinetics of ciprofloxacin. J Ocul Pharmacol, 1993,9: 69-76.
  • 6Baba FZ, Trousdale MD, Gauderman WJ, et al. Intravitreal penetration of oral ciprofloxacin in humans. Ophthalmology,1992,99:483-486.
  • 7JLM. Oral and iv formulations of gatifoxacin cleared for US. market. Am J Health-Syst Pharm, 2000; 57:204
  • 8Hosaka M, Kinoshita S, Toyama A, et al. Antibacterial properties of AM-1155, a new 8-methoxy quinolone. J Antimicrob Chemther,1995; 36:293
  • 9Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin and ofloxacin. Antimicrob Agents Chemother, 1993;37:1259
  • 10Takei M, Fukuda H, Yasue T, et al. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian typeⅡ topoisomerase. Antimicro Agents Chemother, 1998;42:2678

共引文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部